Pancreatic cancer incidence trends in the United States from 2000-2017: Analysis of Surveillance, Epidemiology and End Results (SEER) database

Abstract

Background: Recent incidence trends of pancreatic cancers were reviewed by demographics and histologic type to observe any new findings. Methods: Data was used from the Surveillance, Epidemiology, and End Results (SEER) registry 18 (2000-2017) and it underwent temporal trend analysis. Pancreatic cancer incidence rates were reported based on histological subtype and demographics. Results: The incidence rate of white males increased significantly during 2000-2017 (annual percent change (APC) = 3.5%) compared to previously reported APCs. The incidence of white females grew from an APC of 1.29% to 2.9%. Rates among black ethnicity increased with an APC of 4.2%. Rates among Hispanics and other ethnicities also showed increment. The rates for ductal adenocarcinoma showed a positive trend in all races, with the APC ≥ 6 % for females and APC ≥ 6.5 % for males. The rates of non-secretory endocrine tumors showed a decline in both genders of all five races in recent years after showing an initial positive trend till 2010. Rates for pancreatic adenocarcinoma continued to rise in all ethnicities from 2000-2017. Interestingly, there was a rise in carcinoid type pancreatic neuroendocrine tumors (PNETs) in all ethnicities. Cumulatively, males had a higher incidence than females; male to female Incidence Risk Ratio (IRRs) was 1.32. The IRR was > 1 for age groups ≥ 35 years. The male to female IRRs was less than 1 for cystic adenocarcinoma, secretory endocrine, and solid pseudopapillary carcinomas (IRR = 0.5, 0.9, and 0.2 respectively, confidence intervals 0.4–0.6 and 0.9-1.3, 0.2–0.3, respectively). Conclusion: Pancreatic cancer incidence continued to rise in the years 2000-2017. However, incidence differed by demographics and histologic type. Interestingly, recent years discerned a rise in PNETs (carcinoid type) which has not been reported previously.

Clinicopathological and Prognostic Value of Survivin Expression in Surgically Resected Pancreatic Ductal Adenocarcinoma

“…With an ever increasing incidence year on year [ 5 ], PDAC remains one of the few tumour entities sharing an extremely poor prognosis with an overall 5-year survival rate of 5–10% [ 4 ]. While surgical resection and adjuvant chemotherapy remain indispensable for curative treatment, targeted therapies have been failing to improve patient outcome and long-term survival markedly and, therefore, could not be successfully introduced to the clinical setting of PDAC treatment so far [ 6 ].…”

“…With a persistently rising incidence, pancreatic ductal adenocarcinoma (PDAC) is currently the seventh leading cause of malignoma-related death and is estimated to become the second leading cause of fatalities associated with cancer in 2030 [ 1 , 2 ]. Termed as one of the “recalcitrant” cancers by US legislation [ 3 ], PDAC overall 5-year survival rates remain poor ranging from 5–10% with 80–85% of the patients diagnosed in an advanced or metastatic stage of the disease [ 4 , 5 ]. Further, surgical resection supplemented by an adjuvant chemotherapy remains the only curative therapy approach, whereby only 20% of the patients with localised PDAC reach postoperative 5-year survival [ 6 ].…”

Graph Convolutional Neural Networks for Histological Classification of Pancreatic Cancer

“…and "Suspicious" cases were also excluded due to lack of definitive diagnosis and inter-observer variability. Rarely, some cell blocks from such cases were included in the negative category if they met one of two criteria: (1) The original pathology report described them as negative or unremarkable; (2) They were cleared in blinded review by our senior expert cytopathologist (X.L. ).…”

“…Pancreatic ductal adenocarcinoma (PDAC) is an aggressive type of cancer derived from the epithelial cells that make up the ducts of the pancreas. PDAC ranks firmly last among all cancer types in terms of worst prognostic outcomes 1 , and its incidence and mortality rates have continued to increase for decades in Unites States [2][3][4][5] . According to one study 6 , from 1990 to 2017, the number of cases and deaths worldwide identified as related to pancreatic carcinoma doubled.…”

Prognostic value, immune signature and molecular mechanisms of the SUMO family in pancreatic adenocarcinoma

“…PAAD is prone to distant metastasis, with a high degree of malignancy and poor prognosis, and the 5-year survival rate is only 7.2% ( He et al, 2022 ). Despite great advances in the treatment of PAAD over the past decades, regrettably, the incidence and mortality of this disease have increased worldwide, especially in countries such as the United States, China, and Brazil ( Ali et al, 2021 ; Chaves et al, 2022 ; Yin et al, 2022 ). Recent projections suggest that by 2030, PAAD could surpass colorectal cancer as the second leading cause of cancer-related death after lung cancer ( Ali et al, 2021 ).…”